Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Intravenous amino acids and dextrose provide essential nitrogen and calories for protein synthesis and energy metabolism. Electrolytes maintain osmotic balance and cellular function. Calcium is critical for neuromuscular transmission and bone health.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
Total parenteral nutrition in patients who require combined amino acid, dextrose, and electrolyte supplementation,Peripheral parenteral nutrition when central access is not feasible
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
Intravenous infusion: Adult dose is based on protein and caloric requirements. Typical dose: 1-2 L/day of this 4.25% amino acid, 20% dextrose solution, providing approximately 4.25 g amino acid/100 m L and 680 kcal/L. Infusion rate should be adjusted to avoid hyperglycemia, usually starting at 25-50 m L/hr and increasing gradually.
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Not applicable as a single entity; components have distinct half-lives: dextrose ~1.5-2 hours (glucose); amino acids ~5-10 minutes; electrolytes vary (e.g., calcium ~2-3 hours). Clinical context: continuous infusion achieves steady state.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
Amino acids undergo hepatic metabolism and renal excretion of nitrogenous wastes; dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are excreted renally.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
The amino acids and electrolytes are metabolized or utilized; dextrose is oxidized to CO2 and water. Renal excretion of nitrogen is ~60-80% as urea, with minor losses in feces (5-10%) and skin (2-5%). Electrolytes are excreted primarily renally.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Minimal for most components (<10% for amino acids and electrolytes); calcium ~40% bound to albumin.
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Not applicable as a mixture; individual components vary: dextrose Vd ~0.2 L/kg, electrolytes distribute in total body water (e.g., sodium 0.6 L/kg).
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
Intravenous: 100%.
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
Contraindicated in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²) unless on dialysis. In moderate impairment (e GFR 30-59 m L/min/1.73 m²), reduce dose by 50% and monitor electrolytes.
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
Contraindicated in patients with severe hepatic encephalopathy. In Child-Pugh Class B or C, use with caution; reduce dose by 50% and monitor ammonia levels.
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
Dose based on weight (kg): 2-3 g amino acids/kg/day and 10-20 g dextrose/kg/day. Typical infusion rate: 0.1-0.2 m L/kg/hr initially, titrated to clinical response. Not recommended for neonates due to high dextrose concentration.
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
No specific dose adjustment; use lower initial infusion rates (25-50 m L/hr) due to reduced renal and hepatic function. Monitor glucose and electrolytes closely.
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
Not for use in patients with known hypersensitivity to any component; risk of metabolic acidosis, hyperglycemia, or electrolyte imbalances if not monitored appropriately.
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
Monitor for signs of infection, hyperglycemia, electrolyte disturbances, and fluid overload. Use with caution in patients with renal impairment, hepatic disease, or diabetes. Do not administer simultaneously with blood products through same IV line.
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Known hypersensitivity to any ingredient, severe hyperglycemia, hyperkalemia, hypercalcemia, anuria, or inborn errors of amino acid metabolism.
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
No oral food interactions as this is an intravenous formulation. However, if transitioning to oral intake, monitor for refeeding syndrome and adjust accordingly. Avoid simultaneous administration of medications or other additives unless compatibility confirmed.
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
CLINIMIX E 4.25/20 is a parenteral nutrition solution containing amino acids, electrolytes, and dextrose. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this combination product. Dextrose at high doses may cause fetal hyperglycemia and hyperinsulinemia, potentially leading to neonatal hypoglycemia. Electrolyte imbalances (e.g., calcium) can affect fetal development. Use only if clearly needed and monitor maternal glucose and electrolytes closely. First trimester risks are theoretical; second and third trimester risks include fetal hyperglycemia and electrolyte disturbances.
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
No data on excretion of CLINIMIX E components in breast milk. Dextrose and amino acids are normal milk constituents. Calcium and other electrolytes are present in milk, but parenteral administration may increase levels. M/P ratio not available. Caution: potential for maternal hyperglycemia or electrolyte imbalances affecting milk composition. Use only if clearly needed, and monitor infant for hypoglycemia or electrolyte disturbances.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
Pregnancy increases plasma volume and renal blood flow, potentially lowering serum electrolyte concentrations; adjust electrolyte doses based on frequent monitoring. Glucose tolerance decreases; may require reduced dextrose infusion rate or insulin to maintain euglycemia. Protein requirements increase; amino acid dose may need adjustment. Total fluid volume may need adjustment due to expanded intravascular volume. No standard dose recommendations; individualize based on metabolic status.
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
This total parenteral nutrition formulation provides 4.25% amino acids and 20% dextrose with electrolytes and calcium. Do not add additional calcium or phosphate without compatibility check to avoid precipitation. Use a dedicated line with an inline filter (1.2 micron for lipid-containing, 0.22 micron for non-lipid). Monitor serum glucose, electrolytes, renal and hepatic function. Adjust rate gradually to prevent hyperglycemia or rebound hypoglycemia. Note sulfite-free for sulfite-sensitive patients.
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
This solution is given intravenously to provide nutrition when you cannot eat.,Report any signs of infection at the IV site (redness, swelling, pain) or fever.,You will have regular blood tests to check your sugar, electrolyte, and organ function.,Do not stop or change the infusion rate yourself; it must be adjusted gradually.,Notify your nurse if you experience headache, nausea, sweating, or rapid heartbeat, which may indicate low blood sugar.
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS, answered by our medical review team.
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Intravenous amino acids and dextrose provide essential nitrogen and calories for protein synthesis and energy metabolism. Electrolytes maintain osmotic balance and cellular function. Calcium is critical for neuromuscular transmission and bone health.. AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion: Adult dose is based on protein and caloric requirements. Typical dose: 1-2 L/day of this 4.25% amino acid, 20% dextrose solution, providing approximately 4.25 g amino acid/100 m L and 680 kcal/L. Infusion rate should be adjusted to avoid hyperglycemia, usually starting at 25-50 m L/hr and increasing gradually.. The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 4.25/20 is a parenteral nutrition solution containing amino acids, electrolytes, and dextrose. There are no adequate and well-controlled studies in pregnant women. Anima. AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.